Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586457 | 0.89 | NPY5R (0.44) | OPRM1OPRD1NPY5RAVPR1AHTR2A | |
| SCHEMBL17586460 | 0.85 | AVPR1A (0.48) | OPRM1OPRD1NPY5RAVPR1A | |
| SCHEMBL25866294 | 0.80 | OPRM1 (0.43) | OPRM1OPRD1NPY5RBACE1AVPR1A | |
| SCHEMBL31758718 | 0.79 | NPY5R (0.36) | OPRM1OPRD1NPY5RBACE1CTSD | |
| SCHEMBL12935311 | 0.79 | SIGMAR1 (0.50) | NPY5RAVPR1A | |
| SCHEMBL30476241 | 0.78 | CTSC (0.35) | AVPR1ACTSC | |
| SCHEMBL18373219 | 0.78 | OPRM1 (0.42) | OPRM1OPRD1NPY5RAVPR1ATDP2 | |
| SCHEMBL17586451 | 0.77 | RORC (0.42) | BACE1 | |
| SCHEMBL29922337 | 0.77 | OPRM1 (0.41) | OPRM1OPRD1NPY5RAVPR1ATDP2 | |
| SCHEMBL18373156 | 0.76 | NPY5R (0.45) | OPRM1OPRD1NPY5RAVPR1ATDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | INSMED INCORPORATED (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4646265-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| WO-2024148308-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023134656-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | 上海壹典医药科技开发有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-RE47636-E1 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-3191487-B1 | SPIROCYCLIC INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3511331-A1 | SPIROCYCLIC INHIBITORS OF CATHEPSIN C | Boehringer Ingelheim International GmbH (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-9879026-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879026-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-16 | — | — | US | disclosed |
| US-9540373-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540373-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20160075704-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075704-A1 | NOVEL SUBSTITUTED SPIROCYCLES | CTSC, CTSE, CTSS | OPRM1 2695/4885OPRD1 1610/4885NPY5R 2143/4885 |
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP7, DPP9 | OPRM1 3261/4885OPRD1 758/4885NPY5R 1905/4885 |
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | DPP4, DPP7, DPP9 | OPRM1 3261/4885OPRD1 758/4885NPY5R 1905/4885 |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | CTSC, CTSE, CTSS | OPRM1 2695/4885OPRD1 1610/4885NPY5R 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.